Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corning Incorporated (GLW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Corning IncorporatedTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Corning Incorporated vs Regeneron Pharmaceuticals Inc — how do they compare? Corning Incorporated trades at $166.21 (market cap $137.12B), while Regeneron Pharmaceuticals Inc trades at $795.49 (market cap $82.06B). The key difference: Corning Incorporated is the larger of the two by market cap, and Corning Incorporated pays the higher dividend (0.7%). Which is the better fit depends on your goals.

GLWREGN
Market Cap
$137.12B$82.06B
Sector
TechnologyHealth
52-Week High
$255.79$812.27
52-Week Low
$64.52$555.51
Enterprise Value
$144.00B$76.77B
Dividend Yield
0.7%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corning Incorporated

Corning (GLW) trades at $157.74, down 4.8% in the last session amid broader market volatility. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and projected 2026 revenue growth to $17B. Technical indicators are mixed with a neutral overall signal while valuation metrics remain elevated with a P/E of 73.36. Recent analyst upgrades highlight AI infrastructure and optical communications growth potential.

GLW presents a compelling growth story driven by AI data center demand and optical communications expansion, though premium valuation requires flawless execution. Key risks include competitive pressures in photonics and sensitivity to technology spending cycles. With 57% analyst buy ratings and a $193.33 consensus target offering 23% upside, the stock warrants consideration for growth-oriented investors despite near-term volatility.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Corning Incorporated

Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

Read more on GLW

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN